DOCSLIB.ORG

The Administration of Phenobarbital, Phenaglycodol, Glutethimide, Chlorcyclizine, Chlorpromazine Or Other Different Kinds Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Administration of Phenobarbital, Phenaglycodol, Glutethimide, Chlorcyclizine, Chlorpromazine Or Other Different Kinds Of DIFFERENCES AMONG THE ACTION OF PHENOBARBITAL, METHYLCHOLANTHRENE AND MALE SEX HORMONE ON MICROSOMAL DRUG-METABOLIZING ENZYME SYSTEMS OF RAT LIVER* RYUICHI KATO AND MICHIKO TAKAYANAGHI Department of Pharmacology and Department of Toxicology, National Institute of Hygienic Sciences, Setagaya-ku, Tokyo Received for publication May 30, 1966 The administration of phenobarbital, phenaglycodol, glutethimide, chlorcyclizine, chlorpromazine or other different kinds of drugs induce an increase in the activities of drug-metabolizing enzyme system of liver microsome (1-3). Moreover, the administration of caricnogenic polycyclic hydrocarbons, such as 20 methylcholanthrene or 3,4-benzopyrene also induce an increase in the activities of drug metabolizing enzyme systems of liver microsome (4, 5), however, the enzyme systems stimulated by methylcholanthrene or benzopyrene are apparently different from which stimulated by phenobarbital (4, 6, 7). On the other hand, Brodie et al. demonstrated that the liver microsomes from male rats metabolized hexobarbital more rapidly than the liver microsomes from female rats did and the castration of male rats abolished the sex difference and the administration of teststerone restored the sex difference. More over, Kato et al. demonstrated that synthetic anabolic hormone, such as 4-chlorteststerone increased activities of strychnine on carisoprodol metabolizing enzymes of liver micro somes of castrated male and female rats (8, 9). However, Kato et al. observed that the single injection of phenobarbital or methylcholanthrene increased the activities of the drug-metabolizing enzyme system of liver microsomes already within 24 hours after the administration, while single injection of teststerone did not increase the activities of the enzyme systems and the activities were increased after successive injection of 4-5 days (10). Furthermore, Kato and Gilllette observed that the sex difference in the metabolism of drugs by liver microsomal enzymes was not observed in all of the enzyme systems, and some enzyme systems had no clear sex difference (11). These results indicate that the action of phenobarbital, methylcholanthrene and male sex hormone on microsomal drug-metabolizing enzyme systems of rat liver is likely dif ferent. The purpose of present communication is to elucidate these differences. 加 藤 隆 一 ・高 柳 美 智 子 MATERIALS AND METHODS Female (160 g) and male (180 g) rats of Sprague-Dawley strain were used and in some experiments female and male rats of Wistar strain were also used. The results were almost same in the both strains. Phenobarbital sodium (80 mg/kg) was dissolved in distilled water and methylcholanthrene (40 mg/kg) was dissolved in corn oil and both drugs were given intraperitoneally 72 hours and 48 hours before the sacrifice. Methyl teststerone (10 mg/kg) was dissolved in corn oil and given subcutaneously. Since the results of previous papers (11, 12) and preliminary works indicate that the enzyme systems having clear sex difference were stimulated by the administration of methyl teststerone and other anabolic hormones and in contrast, the enzyme systems having no clear sex difference were not stimulated, in most of experiments male rats were used as substitute for castrated female rats treated with methylteststerone. Preparation of microsomes: The rats were killed by decapitation and the liver was im mediately removed and homogenized in 4 volumes of ice cold 1.15% KC1 solution with a Teflon-glass homogenizer. The homogenate was centrifuged at 9,000 x g for 20 minutes and the supernatant fraction was then centrifuged at 144,000 x g for 1 hour and the microsomes were suspended in 1.15% KC1 solution. Enzyme assays: Drug-metabolizing enzymes; a typical incubation mixture consisted of 2.5 ml of microsomal solution equivalent to 1 g of liver, NADP (1.5 ,umoles), glucose 6-phosphate (50 ,umoles), glucose-6-phosphate dehydrogenase (0.5 units), magnesium chlo ride (25 umoles), nicotinamide (50 ,amoles), 1.4 ml of 0.2 M phosphate buffer (pH 7.4), various substrates (5 moles of aminopyrine, butynamine, N-methylbarbital, N-methyl aniline, N,N'-dimethylaniline, N,N'-dimethylnaphthylamine, diphenhydramine, morphine, meperidine, aniline, neoprotosil ; 4 pmoles of hexobarbital ; 3 pmoles of zoxazolamine , p-nitroanisole, p-nitrobenzoic acid; 2 amoles of pentobarbital, carisoprodol), 0.45 ml of 1.15% KC1 and water to a final volume of 5 ml. The mixtures were incubated for 30 minutes under air except the mixtures containing p-nitrobenzoic acid and neoprotosil which were incubated under an atomosphere of nitrogen. The amount of N-demethyla tion of aminopyrine was estimated by measuring the 4-aminoantipyrine formed accord ing to the method of La Du et al. (13). The amount of N-methylation of butynamine , N-methylbarbital, N-methylaniline, N,N'-dimethylaniline, N,N'-dimethylnaphthylamine, diphenhydramine, morphine, meperidine was estimated by measuring the amount of formaldehyde formed according to the method of Nash modified by Cochin and Axelrod (14). The aliphatic hydroxylation of hexobarbital, pentobarbital and carisoprodol was determined by measuring the disappearance of the substrates according to the methods of Cooper and Brodie, Brodie et al. and Kato et al., respectively (15-17). The aromatic hydroxylation of aniline and zoxazolamine was determined by measuring the disappear ance of the substrates according to the methods described in a previous paper and of Conney et al. (11, 18). O-Demethylation of p-nitroanisole was estimated by measuring the formation of p nitrophenol as described in a previous paper (11). Reduction of neoprontosil was deter mined by estimating the formation of sulfanilamide according to Fouts et al. (19). Reduc tion of p-nitrobenzoic acid was determined by estimating the formation of p-aminobenzoic acid CFouts and Brodie (20)j. Microsomal NADPH-oxidase was assayed spectrophotometrically as described by Gillette et al. (21). Microsomal NADPH-cytocrome c reductase, NADPH-neotetrazolium diaphorase, NADPH-dichlorphenolindophenol diaphorase and NADPH-ferricyanide re ductase were determined according to the methods of Williams and Kamin (22). RESULTS 1. Effect of administration of Phenobarbital or methylcholanthrene on the activities of microsomal N-demethylases of female and male rats Effect of administration of phenobarbital or methylcholanthrene on the activities of microsomal N-demethylases of female and male rats was comparatively investigated. As demonstrated in Figs. 1, 2 and 3, the activities of N-demetylation of aminopyrine, butynamine and diphenhydramine, meperidine, N-methylbarbital and morphine had very marked sex difference, while the activities of N-methylaniline, dimethylaniline and dimethylnaphthylamine had only slight sex difference. The administration of pheno barbital to female rats markedly increased the activities of N-demethylation of all the drugs studied. The rate of the increase was, however, markedly different for each sub strates, for example, the activities of N-demethylation of butynamine, N-methylbarbital FiG. 1. Effect of administration of phenobarbital or methylcholanthrene on the N-demethylations of aminopyrine, butynamine and diphenhydramine. Adult female and male rats treated with phenobarbital (PB, 80 mg/kg, i.p.) or methylcho lanthrene (MC, 40 mg/kg, i.p.) 48 hours and 72 hours before sacrifice. The results are expressed as averages obtained from at least six animals and as percentages of female control. The average enzyme activities of female controls are as follows : Amino pyrine N-demethylation (81 mpmole/g/30 min) butynamine N-demethylation (142 mItmole/g/ 30 min) and diphenhydramine N-demethylation (843 mpemole/g/30 min). FIG. 2. Effect of administration of phenobarbital or methylcholanthrene on the N-demethylations of meperidine, N-methylbarbital and morphine. Adult female and male rats were treated with phenobarbital (80 mg/kg, i.p.) or methyl cholanthrene (40 mg/kg, i.p.) 48 hours and 72 hours before sacrifice. The results are ex pressed as average obtained from at least six animals and as percentages of control female rats. The average enzyme activities of female controls are as follows : Meperidine N-deme thylation (798 mpmole/g/30 min), N-methylbarbital N-demethylation (83 mpmole/g/30 min) and morphine N-demethylation (342 m pmole/g/30 min). FIG. 3. Effect of administration of phenobarbital or methylcholanthrene on the N-demethylations of N-methylaniline, N,N'-dimethylaniline and N,N'-dimethylnaphthylamine. Adult female and male rats were treated with phenobarbital (80 mg/kg, i.p.) or methyl cholanthrene (40 mg/kg, i.p.) 48 hours and 72 hours before sacrifice. The results are expressed as averages obtained from at least six animals and as percentages of control female rats. The average enzyme activities of female controls are as follows : N-Methylaniline N-demetylation (553 mpmole/g/30 min), N,N'-dimethylaniline N-demethylation (425 momole/g/30 min) and N,N'-dimethylamine N-demethylation (716 mpmole/g/30 min). and aminopyrine were increased by 774%, 412% and 280%, respectively, while activities of N-demethylation of diphenhydramine, meperidine, morphine, N-methylaniline, N,N' dimethylaniline and N,N'-dimethylnaphthylamine were increased by 108%, 106%, 71%, 113%, 96% and 59%, respectively. The administration of phenobarbital to male rats also increased the activities of N demethylation less markedly than female rats. In contrast, the administration of methyl cholanthrene to female rats did not increase the activities of N-demethylation of
Load more

Recommended publications
  • United States Patent (19) 11 Patent Number: 4,722,938 Sunshine Et Al
    United States Patent (19) 11 Patent Number: 4,722,938 Sunshine et al. (45. Date of Patent: Feb. 2, 1988 (54 METHODS FOR USING 82,717, copy of patent and English translation thereof; MUSCULOSKELETAL RELAXANTS (10/83). Rego, "Mio-Relaxantes No Tratmento Das Lombalgias 75 Inventors: Abraham Sunshine, New York; Agudas E Das Lombo-Ciaticas Recentes'Muscle Re Eugene M. Laska, Larchmont; laxants in the Treatment of Acute Lumbalgias and Re Carole E. Siegel, Mamaroneck, all of cent Lumbo-Sciatica Cases, Acta Reumatologica Por N.Y. tuguesa, II, 2:363-364, (1974), copy of the original and English translation thereof. 73 Assignee: Analgesic Associates, Larchmont, Schror, "Analgetisch-Antiphlogistische Therapie Von N.Y. Schmerzzustanden des Bewegungsapparates'Anal 21 Appl. No.: 815,502 gesic-Antiphlogistic Therapy of Locomotor System Pain), Therapiewoche, 28, 5657-5663, (1978), copy of the (22 Filed: Jan. 2, 1986 original and English translation thereof. Schar, "Medikamentose Behandlung von Lumbois Related U.S. Application Data chialgien'Drug Treatment of the Lumbago-Sciatic Syndrome), Schweiz, Rundschau Med. (Praxis), vol. 68, 63 Continuation of Ser. No. 686,380, Dec. 26, 1984, aban No. 5, pp. 141-142, (Jan. 30, 1979), copy of original doned. article and English translation thereof. 51 Int. Cl....................... A61K 31/19; A61K 31/27 Kolodny and Klipper, "Bone and Joint Diseases in the Elderly', Hospital Practice, pp. 91-101, (Nov. 1976). (52) - O - 514/479; 514/568 Nascimento, "Use of an Association Containing an An 58 Field of Search ................................ 514/568, 479 algesic, a Muscle Relaxant and Vitamin B Complex in (56) References Cited Degenerative Joint Diseases, Extra-Articular Rheu matic Ailments and Traumatic Afflictions', F med, FOREIGN PATENT DOCUMENTS (BR), 83(3):361-363, (1981), original article and English 2121529 12/1971 France.
    [Show full text]
  • University Microfilms
    INFORMATION TO USERS This dissertation was produced from a microfilm copy of the original document. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the original submitted. The following explanation of techniques is provided to help you understand markings or patterns which may appear on this reproduction. 1. The sign or "target" for pages apparently lacking from the document photographed is "Missing Page(s)". If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting thru an image and duplicating adjacent pages to insure you complete continuity. 2. When an image on the film is obliterated with a large round black mark, it is an indication that the photographer suspected that the copy may have moved during exposure and thus cause a blurred image. You w ill find a good image of the page in the adjacent frame. 3. When a map, drawing or chart, etc., was part of the material being photographed the photographer followed a definite method in "sectioning" the material. It is customary to begin photoing at the upper left hand corner of a large sheet and to continue photoing from left to right in equal sections with a small overlap. If necessary, sectioning is continued again — beginning below the first row and continuing on until complete. 4. The majority of users indicate that the textual content is of greatest value, however, a somewhat higher quality reproduction could be made from "photographs" if essential to the understanding of the dissertation.
    [Show full text]
  • Definition of Controlled Substance Schedules
    UPDATED MARCH 2018 DEFINITION OF CONTROLLED SUBSTANCE SCHEDULES Drugs and other substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15. Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the U.S., their relative abuse potential, and likelihood of causing dependence when abused. Examples of the drugs in each schedule are listed below. Schedule I Controlled Substances Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4- methylenedioxymethamphetamine ("Ecstasy"). Schedule II/IIN Controlled Substances (2/2N) Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence. Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone. Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital. 1 Schedule III/IIIN Controlled Substances (3/3N) Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
    [Show full text]
  • Appendices Feb 2010 Inclusion of Cobalt and 2019 Fei Prohibited
    APPENDIX 2 CLASSIFICATION OF PROHIBITED SUBSTANCES 1. This classification describes the types of Prohibited Substances and places same in specific categories. The list shall be published on the Club’s Notice Board. CLASS I Drugs that have the greatest pharmacological potential to affect the racing performance of a horse and which have no accepted medical use in a racehorse. These include substances which are potent stimulants of the Central Nervous System (CNS). Examples of drugs in this Class include, but are not limited to: Amphetamines, fentanyl, etorphine, cocaine, morphine, meperidine, opiates, opium derivatives, synthetic opiods, psychoactive drugs. CLASS II Drugs that have a high pharmacological potential for affecting the racing performance of a horse. These include: (i) substances which are pharmacologically active in altering the cons (ii) substances which are not generally accepted as therapeutic agents in the racing horse; and (iii) substances, some of which may have legitimate use in equine medicine but should not be found in the racing horse, such as injectable local anaesthetics. 1 Groups of drugs in this Class include, but are not limited to: (a) Opiate partial agonists, or agonistsantagonists; (b) Non-opiate psychotropic drugs, which may have stimulant, depressant, analgesic or neuroleptic effects; (c) Miscellaneous drugs which might have a stimulant effect on the CNS; (d) Drugs with prominent CNS depressant action; (e) Antidepressant and antipsychotic drugs, with or without prominent CNS stimulatory or depressant effects; (f) Muscle blocking drugs which have direct neuromuscular blocking action; (g) Local anaesthetics which have a reasonable potential for use as nerve blocking agents (except procaine); and (h) Snake venom and other biologic substances which may be used as nerve blocking agents.
    [Show full text]
  • Ethiopian Food and Drug Authority Annexs to Cosmetics Import, Export and Wholesale Control Directive No. 48/2020
    Ethiopian Food and Drug Authority Annexs to Cosmetics Import, Export and Wholesale Control Directive No. 48/2020 March, 2020 Addis Ababa, Ethiopia 1 Annexes to the Cosmetics Import, Export and Wholesale Control Directive No. 48/2020 1) Annex I: Illustrative list of cosmetics by catagories 2) Annex II: List of prohibited substances 3) Annex III: List of substances which cosmetic must not contain except the restrictions laid down 4) Annex IV: List of colorants allowed in cosmetics 5) Annex V: List of preservatives allowed in cosmetics 2 Annex I ILLUSTRATIVE LIST OF COSMETICS BY CATEGORIES Creams, emulsions, lotions, gels and oils for the skin (hands, face, feet, etc.) Face masks (with the exception of chemical peeling products) Tinted bases (liquids, pastes, powders) Make-up powders, after-bath powders, hygienic powders, etc. Toilet soaps, deodorant soaps, etc. Perfumes, toilet waters and eau de cologne Bath and shower preparations (salts, foams, oils, gels, etc.) Depilatories Deodorants and anti-perspirants Hair care products hair tints and bleaches products for waving, straightening and fixing setting products o cleansing products (lotions, powders, shampoos) conditioning products (lotions, creams, oils) hairdressing products (lotions, lacquers, brilliantines) Shaving products (creams, foams, lotions, etc.) Products for making-up and removing make-up from the face and the eyes Products intended for application to the lips Products for care of the teeth and the mouth Products for nail care and make-up Products for
    [Show full text]
  • Drug Class Review on Skeletal Muscle Relaxants
    Drug Class Review on Skeletal Muscle Relaxants Final Report Update 2 May 2005 Original Report Date: April 2003 Update 1 Report Date: January 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, MD, MPH, Director Copyright © 2005 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically (see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS Introduction........................................................................................................................4 Scope and
    [Show full text]
  • Drug-Facilitated Sexual Assault Panel, Blood
    DRUG-FACILITATED SEXUAL ASSAULT PANEL, BLOOD Blood Specimens (Order Code 70500) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines, cont. Ethanol Phenylbutazone Phenytoin Cyclizine Amphetamines Piroxicam Pregabalin Diphenhydramine Amphetamine Salicylic Acid* Primidone Doxylamine BDB Sulindac* Topiramate Fexofenadine Benzphetamine Tapentadol Zonisamide Guaifenesin Ephedrine Tizanidine Antidepressants Hydroxyzine MDA Tolmetin Amitriptyline Loratadine MDMA Tramadol Amoxapine Oxymetazoline* Mescaline* Anesthetics Bupropion Pyrilamine Methcathinone Benzocaine Citalopram Tetrahydrozoline Methamphetamine Bupivacaine Clomipramine Triprolidine Phentermine Etomidate Desipramine Antipsychotics PMA Ketamine Desmethylclomipramine 9-hydroxyrisperidone Phenylpropanolamine Lidocaine Dosulepin Aripiprazole Pseudoephedrine Mepivacaine Doxepin Buspirone Analgesics Methoxetamine Duloxetine Chlorpromazine Acetaminophen Midazolam Fluoxetine Clozapine Baclofen Norketamine Fluvoxamine Fluphenazine Buprenorphine Pramoxine* Imipramine Haloperidol Carisoprodol Procaine 1,3-chlorophenylpiperazine (mCPP) Mesoridazine Cyclobenzaprine Rocuronium Mianserin* Norclozapine Diclofenac Ropivacaine Mirtazapine Olanzapine Etodolac Antibiotics Nefazodone Perphenazine Fenoprofen Azithromycin* Nordoxepin Pimozide Hydroxychloroquine Chloramphenicol* Norfluoxetine Prochlorperazine Ibuprofen Ciprofloxacin* Norsertraline Quetiapine Ketoprofen Clindamycin* Nortriptyline Risperidone Ketorolac Erythromycin* Norvenlafaxine Thioridazine Meclofenamic Acid* Levofloxacin* Paroxetine
    [Show full text]
  • On the Approximation of the Laws of the Member States Relating to Cosmetic Products (76/768/EEC )
    27 . 9 . 76 Official Journal of the European Communities No L 262/169 COUNCIL DIRECTIVE of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products (76/768/EEC ) THE COUNCIL OF THE EUROPEAN COMMUNITIES, regards the composition, labelling and packaging of cosmetic products ; Having regard to the Treaty establishing the Euro­ pean Economic Community, and in particular Whereas this Directive relates only to cosmetic prod­ Article 100 thereof, ucts and not to pharmaceutical specialities and medicinal products ; whereas for this purpose it is necessary to define the scope of the Directive by Having regard to the proposal from the Commission, delimiting the field of cosmetics from that of phar­ maceuticals ; whereas this delimitation follows in particular from the detailed definition of cosmetic Having regard to the opinion of the European Parlia­ products, which refers both to their areas of appli­ ment ( 1 ), cation and to the purposes of their use; whereas this Directive is not applicable to the products that fall Having regard to the opinion of the Economic and under the definition of cosmetic product but are Social Committee (2 ), exclusively intended to protect from disease; whereas, moreover, it is advisable to specify that certain prod­ ucts come under this definition, whilst products Whereas the provisions laid down by law, regulation containing substances or preparations intended to be or administrative action in force in the Member ingested, inhaled, injected or implanted in the human States
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Eagling Differential Selectivity of CYP Inhibitors Against Probe Substrates
    Br J Clin Pharmacol 1998; 45: 107–114 Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes Victoria A. Eagling, John F. Tjia & David J. Back Department of Pharmacology & Therapeutics, University of Liverpool, P.O. Box 147, Liverpool L69 3GE, UK Aims Chemical inhibitors of cytochrome P450 (CYP) are a useful tool in defining the role of individual CYPs involved in drug metabolism. The aim of the present study was to evaluate the selectivity and rank the order of potency of a range of isoform-selective CYP inhibitors and to compare directly the eVects of these inhibitors in human and rat hepatic microsomes. Methods Four chemical inhibitors of human cytochrome P450 isoforms, furafylline (CYP1A2), sulphaphenazole (CYP2C9), diethyldithiocarbamate (CYP2E1), and ketoconazole (CYP3A4) were screened for their inhibitory specificity towards CYP- mediated reactions in both human and rat liver microsomal preparations. Phenacetin O-deethylation, tolbutamide 4-hydroxylation, chlorzoxazone 6-hydroxylation and testosterone 6b-hydroxylation were monitored for enzyme activity. Results Furafylline was a potent, selective inhibitor of phenacetin O-deethylation = (CYP1A2-mediated) in human liver microsomes (IC50 0.48 mm), but inhibited both phenacetin O-deethylation and tolbutamide 4-hydroxylation (CYP2C9- mediated) at equimolar concentrations in rat liver microsomes (IC50=20.8 and 24.0 mm respectively). Sulphaphenazole demonstrated selective inhibition of tolbutamide hydroxylation in human liver microsomes but failed to inhibit this reaction in rat liver microsomes. DDC demonstrated a low level of selectivity as an inhibitory probe for chlorzoxazone 6-hydroxylation (CYP2E1-mediated). DDC also inhibited testosterone 6b-hydroxylation (CYP3A-mediated) in man and rat, and tolbutamide 4-hydroxylase activity in rat.
    [Show full text]
  • Commonly Abused Prescription and Otc Medications
    C OMMONLY A BUSED P RESCRIPTION AND OTC MEDIcaTIONS Substance Examples of Commercial and Street Names DEPRESSANTS barbiturates Amytal, Nembutal, Seconal, Phenobarbital; barbs, reds, red birds, phennies, tooies, yellows, yellow jackets Benzodiazepines Ativan, Halcion, Librium, Valium, Xanax; candy, downers, sleeping (other than flunitrazepam) pills, tranks Flunitrazepam Rohypnol; forget-me pill, Mexican Valium, R2, Roche, roofies, (associated with sexual assaults; roofinol, rope, rophies not sold in US, but may be brought in) OPIOIDS AND MORPHINE DERIVATIVES codeine Empirin with Codeine, Fiorinal with Codeine, Robitussin A-C, Tylenol with Codeine; Captain Cody, Cody, schoolboy; (with glutethimide) doors & fours, loads, pancakes and syrup fentanyl and fentanyl analogs Actiq (oral), Duragesic (patch), Sublimaze; Apache, China girl, China white, dance fever, goodfella, jackpot, murder 8, TNT, Tango & Cash morphine Roxanol, Duramorph; M, Miss Emma, monkey, white stuff oxycodone HCL Oxycontin; Oxy, O.C., killer hydrocodone bitartrate, acetaminophen Vicodin; vike, Watson-387 STIMULANTS amphetamine Biphetamine, Dexedrine, Adderall; bennies, black beauties, crosses, hearts, LA turnaround, speed, truck drivers, uppers methylphenidate Ritalin; JIF, MPH, R-ball, Skippy, the smart drug, vitamin R (safe & effective for treatment of ADHD) OVER-THE-COUNTER (OTC) MEDICATION Dextromethorphan (DXM) Found in any cold medicine with “DM” or “Tuss” in the title or name; Orange Crush, Triple C’s, C-C-C, Red Devils, Skittles, Dex, Vitamin D, Robo, Robo-trippin’,
    [Show full text]
  • Chloral Hydrate: Summary Report
    Chloral Hydrate: Summary Report Item Type Report Authors Yuen, Melissa V.; Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Mattingly, Ashlee N. Publication Date 2020-02 Keywords Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration; Chloral Hydrate Rights Attribution-NoDerivatives 4.0 International Download date 26/09/2021 09:06:16 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12087 Summary Report Chloral Hydrate Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy February 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATION ..................................................................................................... 4 METHODOLOGY ...................................................................................................................
    [Show full text]